⌕
Generate Biomedicines Inc · GENB · Nasdaq
Tenet 35 · Weak
⇄ Compare
$13.61−0.19 (−1.40%)
Market open · 15-min delayed · as of 3:53 PM ET

Generate Biomedicines Inc · Overview

Industry: Pharmaceutical Preparations · see every company filed here →

Generate Biomedicines Inc scores 35/100. Weak. Growth is the soft spot versus 400 Healthcare peers. Insufficient inputs: Tenet 35 is built from 3 of 4 pillars, from 25% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=400
35/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
—
Quality
49
Health
47
Growth
9

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Value & Momentum omitted — no data yet.
Value—QualityDHealthDGrowthFMomentum—
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
net income to common shareholders is not on file for this year
P/B
—
no P/B on file
P/S
55.5×
price to sales
ROE
—
negative equity denominator
Operating margin
−737.0%
before interest and tax
Net margin
—
no net margin on file
Current ratio
2.85
fiscal 2025
Net debt / EBITDA
—
negative EBITDA denominator
EPS CAGR 5y
—
needs five years of positive earnings
Market cap
$1.7B
small cap
Div yield
0.00%
reinvests all
52-wk range
11.00 – 22.67
low → high, since listing

Market cap: share price × the latest quarter's diluted weighted-average share count (vendor).

The whole report, at a glance · every card is a live peek, click any to open the section

Tenets
0 / 17
  • ✕ Graham Defensive
  • ✕ Drawdown Context
  • ~ Reversal Evidence
  • ✕ Quality Floor
  • ✕ Trend Alignment
  • ✕ Relative Strength
+11 more →
Financials
Revenue, margins and the five-year statements.
Analyst Forecasts
Consensus estimates are on the Analyst tab.
Earnings
TBA
next report
Beat/miss history appears here after the first tracked report.
Statistics
ROIC−89%
Technical Analysis
Downtrend short-term signal
vs 50-day−10.8%
vs 200-day—
RSI (14)37
News & Insights
Headlines are on the News tab.
Dividends
0.00% yield

Pays no dividend. Every dollar of profit is reinvested into the business.

Ownership
77% institutional

13F flows & insider trades land here.

About Generate Biomedicines Inc

We are a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. Our vision is to program biology to generate optimal therapeutics for the greatest impact on human health. Central to our visio…

Composite computed 2026-10-02 · peer basis: Healthcare (n=400) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

Free account: the funds that hold GENB, and at what weight. Everything else on this page stays open.Create a free account
Methodology© 2026 Tenet Investing Inc. · Toronto, Canada

Data from Intrinio and Financial Modeling Prep.